AppetiteFat LossMetabolism

Tirzepatide

What is Tirzepatide?

Tirzepatide is a dual GIP and GLP-1 receptor agonist. It is the first "twincretin" medication, offering superior weight loss and glycemic control compared to GLP-1 mono-agonists.

Mechanism of Action

Activates both the GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors. GIP activation synergizes with GLP-1 to enhance insulin secretion and improve fat metabolism.

Benefits

  • Superior weight loss vs Semaglutide
  • Improved insulin sensitivity
  • Reduced visceral fat
  • Lower risk of hypoglycemia

Typical Dosage

  • 2.5mg weekly (starting)
  • 5mg, 7.5mg, 10mg, 12.5mg, 15mg weekly (titration steps)

Side Effects

  • Nausea
  • Diarrhea
  • Decreased appetite
  • Dyspepsia

Dosage Protocol

Tirzepatide is administered once weekly via subcutaneous injection. The protocol requires strict titration to mitigate gastrointestinal side effects. Start at 2.5 mg weekly for 4 weeks. Increase to 5 mg weekly for at least 4 weeks. If needed and tolerated, increase in 2.5 mg increments every 4 weeks to target doses of 10 mg or 15 mg. Maximum dose is 15 mg weekly. Administer on the same day each week, with or without food.

Reconstitution

Typically supplied as pre-filled pens or single-dose vials. If lyophilized (research): Reconstitute with bacteriostatic water based on vial size to achieve convenient concentration (e.g., 10mg vial + 1mL water = 10mg/mL).

Dosing Schedule

Standard Protocol

  • •Weeks 1-4: 2.5 mg once weekly
  • •Weeks 5-8: 5 mg once weekly
  • •Weeks 9-12: 7.5 mg once weekly (if needed)
  • •Maintenance: 5mg, 10mg, or 15mg weekly based on response

Negative Interactions

  • Insulin (hypoglycemia risk)
  • Alcohol
  • Other GLP-1 agonists

Tirzepatide is a potent prescription medication. Use under medical supervision. Risk of thyroid C-cell tumors (boxed warning).

HomeLibraryResearchFavoritesToolsVisuals